To Save Pepaxto, Oncopeptides Throws Shade At IMiD Use In Elderly Myeloma Patients

 
• By Sue Sutter
Chain link
Oncopeptides says its withdrawal appeal brief for Pepaxto describes the 'missing link' for why elderly myeloma patients have not seen improved survival. • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards